Company / Revenue
Supernus Pharmaceuticals, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$719.0M
FY2025
5-year range
$579.8M / $719.0M
FY2021-FY2025
Trend
+8.6%
vs FY2024
Sector context
#53 of 155
Health Care
What the data says
At $719M, Supernus Pharmaceuticals, Inc.'s revenue ranks #53 of 155 in the Health Care sector. Revenue has fluctuated over the past 10 years, ranging from $85M in FY2019 to $719M in FY2025.
Based on SEC 10-K filings.
$719M in FY2025 with a 5-year CAGR of +6.7%.
Improved from $608M to $719M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +2.5%
- 5-Year CAGR
- +6.7%
- 10-Year CAGR
- -
Sector benchmark
#53 of 155 in Health CareTop 34% of 155This company $719.0M Sector average $4.5B
▼
-83.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.7%, indicating consistent growth.
- In FY2025, revenue increased 8.6% year-over-year.
- Ranks #53 out of 155 companies in the Health Care sector.
- Lowest revenue in the period was in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $719.0M | +8.6% |
| FY2024 | $661.8M | +8.9% |
| FY2023 | $607.5M | -8.9% |
| FY2022 | $667.2M | +15.1% |
| FY2021 | $579.8M | +11.4% |
| FY2020 | $520.4M | +508.8% |
| FY2019 | $85.5M | -60.2% |
| FY2018 | $215.0M | +45.8% |
| FY2017 | $147.5M | +59.1% |
| FY2016 | $92.7M | -37.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026